drugset / Trial / NCT00920608

A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients

NCT00920608

Phase 1 Withdrawn 12 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The main aim of this clinical study is to investigate whether the blood concentration of methotrexate changes when AZD9056 is co- administered together with methotrexate.

Timeline

Start
2009-05
Primary completion
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD9056 Small molecule 400 mg Oral
Subject Methotrexate Small molecule 7.5 mg Oral
Subject Methotrexate Small molecule 20 mg Oral

Indications